Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01160952
Other study ID # SPO-I-08-CN-041-C
Secondary ID ITRFUN4046
Status Recruiting
Phase Phase 2
First received July 12, 2010
Last updated July 23, 2010
Start date May 2009
Est. completion date March 2011

Study information

Verified date July 2010
Source Guangzhou General Hospital of Guangzhou Military Command
Contact Yonghua Li, MD
Phone 8613751880527
Email lyhood@163.com
Is FDA regulated No
Health authority China: Ethics Committee
Study type Interventional

Clinical Trial Summary

- The primary objective of this study is to evaluate the efficacy and safety profile of itraconazole as in primary prophylaxis

- The second objective of this study is to find the difference between long-term versus short-term sequential therapy of Itraconazole (intravenous followed by oral itraconazole) as primary prophylaxis of invasive fungal infections (IFI) in patients undergoing allogeneic stem cell transplantation (allo-SCT)

- also to explore the relationship between the incidence of IFI with plasma concentrations of itraconazole and hydroxy-itraconazole


Description:

Invasive fungal infections (IFI) remain the major cause of death among neutropenic patients receiving high dose chemotherapy or allo-SCT. Especially, patients undergoing allo-SCT generally receive intensive immunosuppressive therapy, which make those patients at high risk of developing IFI.

Prompt intensive antifungal therapy may increase the incidence rate of IFI and improved responses and survival. Antifungal prophylaxis has been recommended in patients undergoing allo-SCT by Infectious diseases society of America (IDSA) and Chinese guidelines for the diagnosis and management of IFI in patients with hematologic/malignant tumor (revised).

Few studies have addressed the role of previous IFI in the feasibility of stem cell transplant, or the secondary prophylaxis with antifungal drugs in preventing recurrence of infection after transplantation. However, given the lack of prospective studies, the role of primary antifungal prevention and the course of treatment remain unclear.

Itraconazole is a wide-spectrum triazole antifungal agent active against Candida albicans, non-albicans, Aspergillus spp., Blastomyces dermatitidis, Blastomyces coccidioides, Cryptococcus neoformans, Sporothrix schenkii, Paracoccidioides brasiliensis, Histoplasma spp. and various kinds of yeast fungi and mycetes.

The role of itraconazole in IFI prophylaxis has been proved by many interventional studies. However the optimal course of prophylaxis is still unknown,especially in China. In this prospective, multicentric study of primary antifungal prevention, long-term or short-term sequential therapy (intravenous followed by oral itraconazole) will be given at standard dose to patients undergoing allogeneic stem cell transplantation to assess the efficacy and safety of itraconazole in primary prophylaxis, and to analysis the relationship between the incidence rate of IFI with plasma concentrations of itraconazole and hydroxy-itraconazole.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date March 2011
Est. primary completion date December 2010
Accepts healthy volunteers No
Gender Both
Age group 14 Years to 60 Years
Eligibility Inclusion Criteria:

- Man or woman between 14 and 60 years of age, inclusive

- Patients who affected by hematological diseases, receiving allo-SCT

- Patients with no previous proven or probable invasive fungal infections. Patients without microbiological evidence but with effective anti-fungal therapy history are inclusive

- Subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study

Exclusion Criteria:

- Currently taking the contra-indicated medications such as teldane, astemizol, cisapride and HMG-CoA reductase inhibitor(e.g. Simvastatin, lovastatin, oral Midazolam and Triazolam)

- History of allergy or intolerance to imidazole or azoles anti-fungal agents (e.g. Fluconazol, Itraconazole, Ketoconazole, Miconazole, Clotrimazole)

- Pregnant women, lactating women or women of child bearing potential without applying valid contraceptive measures

- Patients with current cardiac dysfunction (especially with congestive heart failure) or with the history of congestive heart failure

- Patients with severe liver dysfunction (aminotransferase levels >= 5 times the upper limit of normal and total bilirubin level >= 3mg/dL(51.3 µmol/L); or the severity of liver dysfunction does not match this criteria but the patient is in bad condition and not suitable for this trial( doctors make the decision);

- Patients with renal insufficiency having serum Ccr level <30ml/min, calculated from the following formula:

Male: Ccr (ml/min)=(140-age)×weight (kg) /(0.8136×Crea (µmol/L) ) Female:Ccr (ml/min)=(140-age)×weight (kg) ×0.85/(0.8136× Crea (µmol/L) )

- Patients received any experimental drug within 14 days before the planned start of treatment.

- Patients with bad whole body status and not suitable for the trial (doctors make the decision)

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
itraconazole
the two groups are defined by different treatment duration

Locations

Country Name City State
China Guangzhou General Hospital of Guangzhou Military Command Guangzhou Guangdong

Sponsors (6)

Lead Sponsor Collaborator
Guangzhou General Hospital of Guangzhou Military Command First Affiliated Hospital, Sun Yat-Sen University, Nanfang Hospital of Southern Medical University, Renmin Hospital of Zhongshan Guangdong, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Zhujiang Hospital

Country where clinical trial is conducted

China, 

References & Publications (3)

Chinese guideline for the diagnosis and management of IFI in patients with hematologic/maliglant tumor (revised). Chinese journal of internal medicine 2007,46(7):607-610.

Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, Nichols WG, Musher B, Corey L. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004 Feb 15;103(4):1527-33. Epub 2003 Oct 2. — View Citation

Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, Leitz GJ, Territo MC. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med. 2003 May 6;138(9):705-13. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary efficacy evaluation the success rate of prophylaxis therapy by itraconazole 90 days No
Secondary group difference evaluation efficacy difference between long-term and short-term groups per success rate at day 90 90 days No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3
Terminated NCT01185223 - Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation Phase 3
Not yet recruiting NCT01212796 - Allo After Allo Stem Cell Transplantation Following Relapse After Allogeneic Transplant in Haematological Malignancies: Retrospective Results of the GETH N/A
Terminated NCT00737113 - Recombinant Human Growth Hormone (RH-GH) For Accelerating Immune Reconstitution Post Unrelated Cord Blood Transplant Phase 1
Recruiting NCT06028828 - Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation Phase 2
Not yet recruiting NCT03964922 - Immunoevasive Tactics Employed by Myeloid Malignancy After Allogeneic Stem Cell Transplantation N/A
Completed NCT03467074 - Role of Interferon-λ and Vaccine Response
Completed NCT02273024 - Exercise Prior to Allogeneic Hematologic Stem Cell Transplantation N/A
Recruiting NCT06093334 - Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD N/A
Recruiting NCT03286530 - Ruxolitinib + Allogeneic Stem Cell Transplantation in AML Phase 2
Completed NCT01092026 - Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells N/A
Recruiting NCT00883714 - Exercise During the Allogeneic Stem Cell Transplantation Phase 3
Completed NCT04628338 - IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation Early Phase 1
Completed NCT06256341 - HHV-6-specific T-cell Reconstitution Among Children and Adolescents After Allogeneic Stem.
Completed NCT05088941 - Impact of COVID-19 Pandemic on Allogeneic Stem Cell Transplantation Organization : a French Experience
Not yet recruiting NCT06453460 - Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla Phase 2
Recruiting NCT02533947 - Cognition in Allogeneic Stem Cell Transplanted Patients and Sports N/A
Completed NCT01560689 - Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans Following Stem Cell Transplantation Phase 2
Not yet recruiting NCT06297629 - A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation Phase 2
Completed NCT01929980 - Bortezomib to Treat Significant Complication of HSCT Phase 2